Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?
Íñigo Rúa-FigueroaI Altabás-GonzálezC MouriñoK RobertsA Hernández-MartínI Casafont-SoléJ Font-UrgellesJ A Román-IvorraM de la Rubia NavarroM Galindo-IzquierdoT C Salman-MonteJ NarváezP Vidal-MontalM J García-VillanuevaS Garrote-CorralM A Blazquez-CanameroCarlos Marras Fernandez-CidM Piqueras-GarcíaJ Martínez-BarrioM Sánchez-LucasJ Cortés-HernándezE PenzoJ CalvoJ R de DiosB Alvarez-RodríguezM Vasques-RochaE TomeroR Menor-AlmagroM GandíaJ A Gómez-PuertaB Frade-SosaC Ramos-GiráldezC Trapero-PérezE DiezC MorianoA Muñoz-JiménezJ M Pego-ReigosaPublished in: Rheumatology (Oxford, England) (2024)
Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clinical or serologic activity may be observed in some patients. Consequently, tighter post-reduction follow-up is advisable.